# DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE
> **NDA212527** · New Drug Application · Sponsor: CIPLA USA INC. · Approved 2022-03-30
## Drug
- **FDA Application Number:** NDA212527
- **Application type:** New Drug Application
- **Brand name:** DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE
- **Generic name:** Dolutegravir Lamivudine Tenofovir Alafenamide
- **Active ingredients:** DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE
- **Dosage form:** TABLET
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** CIPLA USA INC.
- **First approval:** 2022-03-30
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212527)
---
*MORVS · CC0 1.0*